Search Results - "Lisby, S"

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma by Lokhorst, Henk M, Plesner, Torben, Laubach, Jacob P, Nahi, Hareth, Gimsing, Peter, Hansson, Markus, Minnema, Monique C, Lassen, Ulrik, Krejcik, Jakub, Palumbo, Antonio, van de Donk, Niels W.C.J, Ahmadi, Tahamtan, Khan, Imran, Uhlar, Clarissa M, Wang, Jianping, Sasser, A. Kate, Losic, Nedjad, Lisby, Steen, Basse, Linda, Brun, Nikolai, Richardson, Paul G

“…Daratumumab was associated with impressive antitumor responses, including complete and very good partial responses, in heavily pretreated patients with…”
Get full text

Decrease in nickel sensitization in a Danish schoolgirl population with ears pierced after implementation of a nickel-exposure regulation by Jensen, C.S., Lisby, S., Baadsgaard, O., Vølund, A., Menné, T.

“…Summary Background To reduce the skin nickel exposure of the population the Danish Ministry of Environment issued a regulation that was implemented in 1992,…”
Get full text

Transcriptional regulation of tumor necrosis factor-α in keratinocytes mediated by interleukin-1β and tumor necrosis factor-α by Lisby, S., Hauser, C.

“…: Irritant contact dermatitis (ICD) is an inflammatory skin reaction in which cytokines are thought to play a crucial role. In particular, tumor necrosis…”
Get full text

Nickel‐induced proliferation of both memory and naive T cells in patch test‐negative individuals by LISBY, S, HANSEN, L. H, MENNE, T, BAADSGAARD, O

“…Lymphocyte transformation test has often been used as an in vitro test for nickel allergy. We have previously demonstrated the presence of nickel‐reactive T…”
Get full text

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma by Dimopoulos, Meletios A, Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J, Usmani, Saad Z, Rabin, Neil, Orlowski, Robert Z, Komarnicki, Mieczyslaw, Suzuki, Kenshi, Plesner, Torben, Yoon, Sung-Soo, Ben Yehuda, Dina, Richardson, Paul G, Goldschmidt, Hartmut, Reece, Donna, Lisby, Steen, Khokhar, Nushmia Z, O’Rourke, Lisa, Chiu, Christopher, Qin, Xiang, Guckert, Mary, Ahmadi, Tahamtan, Moreau, Philippe

“…The addition of daratumumab to lenalidomide and dexamethasone resulted in superior response rate and progression-free survival, as compared with lenalidomide…”
Get full text

Association of TNFA gene polymorphism at position -308 with susceptibility to irritant contact dermatitis by Allen, M H, Wakelin, S H, Holloway, D, Lisby, S, Baadsgaard, O, Barker, J N, McFadden, J P

“…Mechanisms underlying susceptibility to skin irritants are not clearly understood. Cytokines play a key role in inflammation, and functional polymorphisms in…”
Get full text

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial by Lonial, Sagar, Prof, Weiss, Brendan M, Prof, Usmani, Saad Z, Prof, Singhal, Seema, Prof, Chari, Ajai, Prof, Bahlis, Nizar J, Prof, Belch, Andrew, Prof, Krishnan, Amrita, Prof, Vescio, Robert A, Prof, Mateos, Maria Victoria, Prof, Mazumder, Amitabha, Prof, Orlowski, Robert Z, Prof, Sutherland, Heather J, Prof, Bladé, Joan, Prof, Scott, Emma C, Prof, Oriol, Albert, MD, Berdeja, Jesus, MD, Gharibo, Mecide, Prof, Stevens, Don A, MD, LeBlanc, Richard, Prof, Sebag, Michael, Prof, Callander, Natalie, Prof, Jakubowiak, Andrzej, Prof, White, Darrell, Prof, de la Rubia, Javier, Prof, Richardson, Paul G, Prof, Lisby, Steen, MD, Feng, Huaibao, PhD, Uhlar, Clarissa M, PhD, Khan, Imran, MD, Ahmadi, Tahamtan, MD, Voorhees, Peter M, Prof

“…Summary Background New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs…”
Get full text

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial by Hillmen, Peter, Prof, Robak, Tadeusz, MD, Janssens, Ann, MD, Babu, K Govind, MD, Kloczko, Janusz, MD, Grosicki, Sebastian, MD, Doubek, Michael, MD, Panagiotidis, Panagiotis, MD, Kimby, Eva, MD, Schuh, Anna, MD, Pettitt, Andrew R, MRCPath, Boyd, Thomas, MD, Montillo, Marco, MD, Gupta, Ira V, MD, Wright, Oliver, BSc, Dixon, Iestyn, BSc, Carey, Jodi L, RN BSN, Chang, Chai-Ni, MS, Lisby, Steen, MD, McKeown, Astrid, PhD, Offner, Fritz, MD

“…Summary Background Treatment for patients with chronic lymphocytic leukaemia who are elderly or who have comorbidities is challenging because fludarabine-based…”
Get full text

74P Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB) by Morgenstern, D.A., Mora, J., Chan, G.C., Nysom, K., Bear, M., Dalby, L. Worsaae, Lisby, S., Kushner, B.H.

Get full text

75P Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): A humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB) by Mora, J., Chan, G.C., Morgenstern, D.A., Nysom, K., Bear, M., Dalby, L. Worsaae, Lisby, S., Kushner, B.H.

Get full text

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study by Wierda, William G., Padmanabhan, Swaminathan, Chan, Geoffrey W., Gupta, Ira V., Lisby, Steen, Österborg, Anders

“…Ofatumumab, the human CD20 monoclonal antibody that binds a distinct epitope from rituximab, has demonstrated clinical benefit as monotherapy for patients with…”
Get full text

Intercellular adhesion molecule-I (ICAM-I) expression correlated to inflammation by Lisby, S, Ralfkiaer, E, Rothlein, R, Vejlsgaard, G L

“…The presence of intercellular adhesion molecule-I (ICAM-I) on keratinocytes of psoriatic skin lesions before and during 8-methoxapsoralen and UVA light (PUVA)…”
Get more information

Nickel-induced activation of T cells in individuals with negative patch test to nickel sulphate by LISBY, S, HANSEN, L. H, SKOV, L, MENNE, T, BAADSGAARD, O

“…Contact hypersensitivity to nickel is the most common form of allergic contact dermatitis. To gain insight into the induction of this frequent disease, T cell…”
Get full text

Levels of enzymatic antioxidants activities in mononuclear cells and skin reactivity to sodium dodecyl sulphate by Camera, E, Lisby, S, Dell'Anna, M L, Santucci, B, Paganelli, R, Baadsgaard, O, Picardo, M

“…Chemical irritants are able to produce several biological modifications of the skin, including the direct or indirect production of cytokines and reactive…”
Get more information

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma by Dimopoulos, Meletios A., Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J., Usmani, Saad Z., Rabin, Neil, Orlowski, Robert Z., Komarnicki, Mieczyslaw, Suzuki, Kenshi, Plesner, Torben, Yoon, Sung-Soo, Ben Yehuda, Dina, Richardson, Paul G., Goldschmidt, Hartmut, Reece, Donna, Lisby, Steen, Khokhar, Nushmia Z., O’Rourke, Lisa, Chiu, Christopher, Qin, Xiang, Guckert, Mary, Ahmadi, Tahamtan, Moreau, Philippe

Get full text

A phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors by Chenard-Poirier, M., Hong, D.S., Coleman, R., de Bono, J., Mau-Sorensen, M., Collins, D., Lisby, S., Basse, L., Lassen, U.

Get full text

A phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors by Chenard-Poirier, M., Hong, D.S., Coleman, R., de Bono, J., Mau-Sorensen, M., Collins, D., Lisby, S., Basse, L., Lassen, U.

Get full text

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma by Kim, Youn H., Duvic, Madeleine, Obitz, Erik, Gniadecki, Robert, Iversen, Lars, Österborg, Anders, Whittaker, Sean, Illidge, Timothy M., Schwarz, Thomas, Kaufmann, Roland, Cooper, Kevin, Knudsen, Kim M., Lisby, Steen, Baadsgaard, Ole, Knox, Susan J.

“…The efficacy and safety of zanolimumab in patients with refractory cutaneous T-cell lymphoma (CTCL) have been assessed in two phase 2, multicenter,…”
Get full text

A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer by Vergote, I., Dean, E., Lassen, U., de Bono, J., Drew, Y., Machiels, J-P., Nielsen, D., Arkenau, H-T., Forster, M., Jones, R., Slomovitz, B., Spicer, J., Johnson, M., Cornez, N., Gennigens, C., Fulton, B., Lisby, S., Basse, L., Coleman, R., Hong, D.S.

Get full text

Daratumumab. Anti-CD38 monoclonal antibody, treatment of multiple myeloma by Richardson, P., Lokhorst, H., Palumbo, A., Nahi, H., Laubach, J., Gimsing, P., Lisby, S., Cakana, A., Brun, N.C., Plesner, T.

Get full text